Voyager Therapeutics Q1 revenue declines, net loss narrows; first patient dosing set for H2 2026

Voyager Therapeutics

07/05/2026 21:11

Overview

US biotechnology firm's Q1 collaboration revenue fell yr/yr as partnerships matured beyond research

Net loss for Q1 narrowed yr/yr, reflecting cost-cutting and efficiency initiatives

Company ended Q1 with $172 mln cash, projecting runway into 2028

Outlook

Company expects first-in-human dosing of VY1706 in Alzheimer’s disease in H2 2026

Company expects tau PET imaging efficacy data for VY7523 in H2 2026

Voyager expects its cash position to fund operations into 2028

Result Drivers

REVENUE DECLINE FROM PARTNERSHIPS - Co attributed lower collaboration revenue to maturation of Neurocrine and Novartis partnerships beyond research phase

COST-CUTTING INITIATIVES - Co said lower R&D and administrative expenses were primarily due to cost-cutting and efficiency initiatives

PIPELINE ADVANCEMENT COSTS - Increased spending on tau silencing gene therapy program (VY1706) as it advanced toward clinical trials

Company press release: ID:nGNX4pbJX1

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q1 Collaboration Revenue
$2.59 mln
Q1 Net Income
-$27.94 mln
Q1 Basic EPS
-$0.47
Q1 Operating Income
-$30.27 mln
Q1 Pretax Profit
-$27.92 mln


Analyst Coverage

The current average analyst rating on the shares is "strong buy" and the breakdown of recommendations is 11 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"

The average consensus recommendation for the biotechnology & medical research peer group is "buy."

Wall Street's median 12-month price target for Voyager Therapeutics Inc is $18.00, about 331.7% above its May 6 closing price of $4.17

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)